NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Benitec Biopharma Inc. BNTC
7 fiscal years on record · USD · FY2024 reported · SEC filings only
$-37.9M
$-23.6M
Growth
—
Revenue, FY2024 · full 7-year series below
Revenue $M
Net income $M
FY2023 · Revenue 0.0 · Net income -21.8
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2022 · Operating -25441.3% · Net -26082.7%
ROE
FY2024 · ROE -52.5%
Each USD of equity lost 52 cents this year.
The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue $B | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 |
| Income tax $B | · | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 |
| EPS, diluted $ | −1.05 | −1.22 | −14.12 | −37.88 | −3.23 | −8.10 | 3.05 |
| Dividend / sh $ | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · |
| ROE % | −52.5 | −91.7 | −1268.6 | −159.1 | −91.8 | −61.7 | 15.7 |
| Shares out B | 0.03 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 28 reconciliationsAUDITED
Reconciled in 7 of 19 fiscal years. 48 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2018